# Planning document for CounterACT experiments (version 1.04a)

Preamble: This document is intended to provide a brief, structured means for assessing the goals of an experiment and whether the study design, study variables, sample size, planned statistical analysis, randomization scheme and study timeline are well-aligned with the goals. It should be completed by the Core C statistical consultant in collaboration with Project personnel. Example entries are shown in italicized font.

# Research Question(s) (in PICO format (https://guides.nyu.edu/c.php?g=276561&p=1847897)) or Milestone Being Addressed (quote milestone text):

*In the TETS/SE model, is perampenal more effective than midazolam in reducing the duration of seizures or the associated mortality?* 

*In the TETS/SE model, is perampenal more effective than diazepam in reducing the duration of seizures or the associated mortality?* 

## **Experimental model:** *TETS/SE mouse model*

#### **Outcome Table:**

Construct	Operationalization / reliability evidence level / blinded assessors	Timing	Distribu- tion type	Anticipated model	Priority
Seizure duration/mortality	Animals instrumented for EEG & videotaped. Dorota scores for presence of [detail particular seizure feature(s) of interest]. Composite indicator for seizure/death is made for each minute. /Low evidence for reliability /Not blinded	Minute-by- minute, up to 180 minutes post- intoxication, with treatment typically administered at 10 or 40 minutes	Binary	Composite outcomes formed by partitioning follow-up time into three periods ([0, 45), [45, 90), and 90+ minutes) and summing the minute-to- minute counts for the period Mixed-effects Poisson	Primary
Convulsions/mortality	<i>u</i>	"	"	"	Secondary

**Notes:** Reliability evidence level should be scored as follows:

*High:* Operationalization is (i) purely objective measurements from laboratory instruments not prone to significant operator or batch effects or (ii) involves a subjective component where relevant evidence for reliability is available from studies in multiple labs

*Medium:* Operationalization is (i) purely objective measurements from laboratory instruments prone to operator or batch effects or (ii) involves a subjective component where relevant evidence for reliability is available from single-lab studies

*Low:* Operationalization involves a subjective component and no formal evidence for reliability is available. (Formal evidence could include reliability studies undertake in our own lab that aim to estimate the between-rater reliability of the measurement process.)

## Concurrent comparison groups (including relevant dosing information) and sample size

Vehicle control for Perampenal (x.xx dose, 40 minutes) (n = XX)

Vehicle control for Midazolam (x.xx dose, 40 minutes) (n = XX)

Midazolam (x.xx dose, 40 minutes) (n = XX)

Perampenal (x.xx dose, 40 minutes) (n = XX)

#### Historical comparison groups (including relevant dosing information), sample size

(Source files for historical controls: DZP\_MDZ\_cleaned\_102915V5ExtraSurvivalData.csv & forStat DZP\_MDZ\_cleaned\_102915V5.csv from folder H:\CounterAct\Project1\Seizure\Data\forStat\_)

Vehicle control for Diazepam (x.xx dose, 40 minutes) (n = XX)

Diazepam (x.xx dose, 40 minutes) (n = XX)

Vehicle control for Midazolam (x.xx dose, 40 minutes) (n = XX)

Midazolam (x.xx dose, 40 minutes) (n = XX)

**Sample Size justification:** Using results from previous studies, we applied the exemplary dataset method to determine that the given sample sizes would provide 80% power (two-sided alpha=5%) to detect incidence rate ratios of 0.50 or greater.

Randomization plan (brief mention of scheme and personnel who will ensure valid randomization):

Anticipated date when final study data will become available to Core C for analysis: mid-May, 2016

**Anticipated turn-around time for Core C analysis** (this would typically be at 4 to 6 weeks, given the three major analysis tasks [plan, implement, and review] and the many other commitments of Core C personnel): *4 weeks* 

#### Date experiment plan was initiated:

List (with dates) of all major changes, including changes to experimental design, choice of comparators, sample size, or study endpoints

Date of last revision: